Quickly find freely available drug and population models in our PBPK model repository.
The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.>
You can use a suffix operator (*) as the placeholder for end of a term. The query must start with at least one alphanumeric character before the suffix operator. E.g., Rifam* will get you “Rifampicin” and “Rifampin”. For more advanced searching tips click here.
Brand Name(s) include: Coartem (artemether, lumefantrine), Riamet (artemether, lumefantrine)
Disease: Malaria
Drug Class: Antimalarials
Related Files: Artemether – drug partner in fixed dose combinations
Date Updated: December 2022
Absorption Model |
|
Volume of Distribution Details |
Note: Kp scalar and Kp adipose used |
Route of Elimination |
CYP3A4 (40%); non-specific hepatic metabolism (60%) |
Perpetrator DDI |
|
Validation |
|
Limitations |
|
Updates in V19 |
|
The RES-Chlorzoxazone file was primarily developed as an inhibitor of CYP3A4. This document provides: 1. Examples of model performance 2. A summary of the key pharmacokinetic features of Chlorzoxazone considered within the model.
Brand Name(s) include: Basoquin, Camoquin, Flavoquin, Coarsucam
Disease: Malaria
Drug Class: Antimalarials
Date Updated: June 2021
Absorption Model |
First-Order |
Volume of Distribution |
Full PBPK (Method 2) |
Route of Elimination |
CYP2C8 = 72%; Additional HLM = 28% |
Perpetrator DDI |
|
Validation |
|
Limitations |
|
Updates in V19 |
|
12 |